Can a GLP-1 ease knee pain after menopause?

# Can a GLP-1 ease knee pain after menopause?

If your knees started aching in the same years your periods became unpredictable, that timing is not a coincidence you invented. After menopause, two things move at once: weight tends to climb, and the drop in estrogen reaches the joints themselves. This piece walks through why the post-menopause knee is under more load, what a large randomized trial actually found when a weight medicine was used in people with obesity and knee osteoarthritis, and where the evidence is solid versus where it is a fair extrapolation.

Key takeaways

Dr. Linda's take

Women come to me describing the same two-part story. The scale drifted up after menopause, and the knees started complaining on the stairs. It is easy to treat those as separate problems, but they usually are not. The knee is a weight-bearing joint, so the pounds and the pain tend to travel together.

Estrogen loss is the other half of the story, and it is the part women are rarely told about. When it comes to the knee, both the extra load and the hormonal shift are pushing in the same direction, which is why this cluster shows up so reliably after the final period. We wrote separately about the weight side in weight gain after menopause and the bone side in bone density after menopause.

So when someone asks whether a weight medicine could take pressure off her knees, I answer two questions at once. Is there trial evidence that weight loss from a GLP-1 reduces knee pain? Yes, and it is good evidence. Was that trial designed around post-menopause women specifically? No, so I hold the finding honestly. If you want a general, no-pressure starting point, our eligibility quiz is education, not a plan for your specific joints.

Why does knee pain get worse after menopause?

Because two separate forces converge on the same joint during these years.

The first is mechanical. Osteoarthritis is a type of arthritis that only affects the joints, usually in the hands, knees, hips, neck, and lower back. The knee carries body weight with every step, and after midlife, osteoarthritis is more common in women than in men.

The second force is hormonal, and it is easy to miss. Osteoporosis and osteoarthritis often coexist in postmenopausal women, imposing a notable burden on mobility and quality of life. Estrogen deficiency, a key characteristic of menopause, represents an important, unifying risk factor that accelerates systemic bone loss while exacerbating osteochondral degeneration. In other words, estrogen deficiency reshapes bone remodeling and cartilage metabolism, so the tissue itself changes, not just the load on top of it. If the bone side of that is what worries you most, bone density after menopause is the companion piece.

Does extra weight load the knee?

Yes, and it is one of the clearest, least controversial parts of this whole picture.

Extra weight puts more stress on your joints. Because the knee bears weight with every stride, that stress lands there hard. This is also why weight loss is a first-line, non-drug lever for knee osteoarthritis in the first place. Weight reduction has been shown to alleviate symptoms of osteoarthritis of the knee, including pain. That single fact is the bridge between a weight medicine and a knee outcome: if the medicine reliably lowers weight, there is a plausible, mechanism-based reason the knee could feel it.

Can a GLP-1 reduce knee osteoarthritis pain?

This is where the strongest evidence sits, and it is a real randomized trial rather than a hopeful guess.

In the STEP 9 trial, adults with obesity and moderate knee osteoarthritis were randomly assigned, in a 2:1 ratio, to receive once-weekly subcutaneous semaglutide (2.4 mg) or placebo over 68 weeks. This population maps closely onto the reality after menopause: in that trial, a total of 81.6% of the participants were women. On the weight endpoint, the mean change in body weight from baseline to week 68 was -13.7% with semaglutide and -3.2% with placebo. On the pain endpoint, the mean change in the WOMAC pain score at week 68 was -41.7 points with semaglutide and -27.5 points with placebo. Function moved too. Participants in the semaglutide group had a greater improvement in SF-36 physical-function score than those in the placebo group.

The trial's own conclusion is measured, and I keep it that way. Among participants with obesity and knee osteoarthritis with moderate-to-severe pain, treatment with once-weekly injectable semaglutide resulted in significantly greater reductions in body weight and pain related to knee osteoarthritis than placebo.

Is the pain relief from the medicine or the weight loss?

Mostly the weight loss, and that distinction matters for how you read the result.

These medicines are weight medicines, not painkillers designed for the joint. The knee benefit rides on the same weight change these drugs are known for elsewhere. In the STEP 1 trial, once-weekly semaglutide 2.4 mg reduced body weight by 14.9% from baseline over 68 weeks, compared with 2.4% in the placebo group. When that much weight comes off a weight-bearing joint, less force crosses the knee with every step, which is the most likely engine behind the pain scores. So these medicines are not treating osteoarthritis directly; they are removing a major mechanical driver of it.

What does this mean for women after menopause?

It means the mechanism is genuinely relevant to you, with one honest caveat.

The STEP 9 population was mostly women and matches the load-plus-pain reality that follows menopause, which is why the finding travels well to this group. But the trial did not select or analyze participants by menopausal status, so a knee benefit in a post-menopause woman is a well-supported extrapolation rather than a result measured in post-menopause women specifically. Whether any medicine belongs in your plan depends on far more than a sore knee, and it is not a decision an article can make for you. If the heart is also on your mind in these years, heart disease risk after menopause is the next read.

Frequently asked questions

Does losing weight actually help knee arthritis?

Yes, and this is well established independent of any drug. Weight reduction has been shown to alleviate symptoms of osteoarthritis of the knee, including pain. The reason is mechanical: extra weight puts more stress on your joints, and the knee bears that weight with every step.

How much did knee pain improve in the GLP-1 trial?

In the STEP 9 trial, the mean change in the WOMAC pain score at week 68 was -41.7 points with semaglutide and -27.5 points with placebo. That was alongside a weight difference, where the mean change in body weight from baseline to week 68 was -13.7% with semaglutide and -3.2% with placebo.

Was the knee trial done in women after menopause?

Not specifically. A total of 81.6% of the participants were women, so the result is highly relevant to women, but the trial did not select or analyze participants by menopausal status. A benefit in a post-menopause woman is a fair extrapolation, not a measured menopause-specific outcome.

Why does menopause itself matter for the knee?

Because the hormone change reaches the joint. Estrogen deficiency, a key characteristic of menopause, represents an important, unifying risk factor that accelerates systemic bone loss while exacerbating osteochondral degeneration. That is on top of the added mechanical load from midlife weight gain.

References

1. MedlinePlus (National Library of Medicine). Osteoarthritis. https://medlineplus.gov/osteoarthritis.html (Accessed 2026-07-27).
2. Mol Med Rep (2026). Estrogen deficiency as a common driver and integrative mechanism in osteoporosis-osteoarthritis comorbidity (Review). PubMed PMID 42169635. https://pubmed.ncbi.nlm.nih.gov/42169635/ (Accessed 2026-07-27).
3. N Engl J Med (2024). Once-Weekly Semaglutide in Persons with Obesity and Knee Osteoarthritis (STEP 9). PubMed PMID 39476339. https://pubmed.ncbi.nlm.nih.gov/39476339/ (Accessed 2026-07-27).
4. N Engl J Med (2021). Once-Weekly Semaglutide in Adults with Overweight or Obesity (STEP 1). PubMed PMID 33567185. https://pubmed.ncbi.nlm.nih.gov/33567185/ (Accessed 2026-07-27).

---

*This article is general education and is not medical advice. It cannot tell you what is right for your body. Talk with a licensed clinician about your own situation.*

*Written and clinically reviewed by Dr. Linda Moleon, MD. Last reviewed 2026-07-27.*